Overview

* Champions Oncology ( CSBR ) fiscal Q4 revenue beats analyst expectations, per LSEG data

* Adjusted EBITDA for fiscal Q4 beats consensus, reflecting operational efficiency

* Fiscal 2025 revenue grows 14% yr/yr, driven by new data business

Outlook

* Champions Oncology ( CSBR ) expects continued revenue growth in fiscal 2026

* Company confident in further monetization of data offering

* Champions sees strong pipeline heading into fiscal 2026

Result Drivers

* DATA BUSINESS - New high-margin data business contributed $4.7 mln to annual revenue, driving overall growth

* OPERATIONAL EFFICIENCY - Disciplined execution and operational improvements led to record adjusted EBITDA and reduced costs

* MARKETING EXPENSES - Increased sales and marketing expenses due to expansion of data business development team and more conferences

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $12.30 $12 mln

Revenue mln (1

Analyst)

Q4 EPS -$0.13

Q4 Beat -$1.02 -$2.48

Adjusted mln mln (1

EBITDA Analyst)

Q4 Gross 41.0%

Margin

Q4 Beat -$2 mln -$3.23

Income mln (1

from Analyst)

Operatio

ns

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Champions Oncology Inc ( CSBR ) is $12.00, about 34.6% above its July 22 closing price of $7.85

* The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 38 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)